DAWNZERA Approved as First RNA Prophylactic Hereditary Angioedema Treatment
August 22, 2025
DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control Ionis Pharmaceuticals, Inc. has shared that the U.S. Food and Drug Administration